Perspectives of people with inherited retinal diseases on ocular gene therapy in Australia: protocol for a national survey.

ABSTRACT:

Introduction

Voretigene neparvovec-rzyl (Luxturna) was approved by the Australian Therapeutic Goods Administration on 4 August 2020 for the treatment of biallelic mutations in the RPE65 gene, a rare cause of congenital and adult-onset retinal dystrophy (predominantly Leber congenital amaurosis). Previous studies have shown that individuals who might participate in gene therapy trials overestimate clinical effect and underestimate risks. However, little is known about the perspectives of patients who may be offered approved gene therapy treatment for ocular conditions (as distinct from participating in clinical trials of gene therapy). The main objective of this study is to develop a tool to assess knowledge, attitudes and perceptions of approved and future genetic therapies

SUBMITTER: Mack HG 

PROVIDER: S-EPMC8220456 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature